'Vance-Led Task Force Set to Remove 760,000 Allegedly Fraudulent Obamacare Enrollments' - WSJ Exclusive
https://www.wsj.com/politics/policy/vance-led-task-force-set-to-remove-760-000-allegedly-fraudulent-obamacare-enrollments-0fbb72d7
Stocks · News reference
Analysts review high-yield healthcare stocks CVS, Viatris and Medtronic, citing ratings, price targets, dividend yields and recent company news.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
https://www.wsj.com/politics/policy/vance-led-task-force-set-to-remove-760-000-allegedly-fraudulent-obamacare-enrollments-0fbb72d7
CVS Health stock declined 1.4% to $87.60, underperforming the broader market which gained 1.49%. The stock has fallen 4.49% over the past month. The company is expected to report flat EPS of $1.6 for the upcoming quarter with revenue projected at $105.04 billion (up 2.11% YoY). CVS holds a Zacks Rank #3 (Hold) rating and trades at a Forward P/E of 11.07, below its industry average of 17.31.
CVS, Steris and Baxter are oversold healthcare stocks with RSI readings near or below 30, potentially offering undervalued buying opportunities.
The global Cardiorespiratory Assessment Units Market is projected to grow from USD 1.48 billion in 2025 to USD 2.98 billion by 2035, expanding at a CAGR of 7.23%. Growth is driven by rising prevalence of COPD and heart failure, innovation in portable AI-enabled systems, and expanding remote care applications. However, high equipment costs and staffing requirements remain challenges. North America leads with 35.12% market share.
ResearchAndMarkets.com released a comprehensive market report on Mexico's cardiac rhythm management devices sector, covering CRT, ICDs, and pacemakers through 2036. The report provides revenue forecasts, sales volume data, pricing analysis, and 2025 competitive positioning for major market players, supporting strategic decision-making for manufacturers, investors, and healthcare stakeholders.
Shopify and Intuitive Surgical, despite significant year-to-date declines of 19% and 29% respectively, present attractive buying opportunities. Shopify's strong Q2 results and AI-powered initiatives position it well in e-commerce, while Intuitive Surgical's market leadership in robotic-assisted surgery and high switching costs provide competitive advantages despite increased competition from Medtronic.